WO2023131841 - R-MDMA AND S-MDMA TO ASSIST PSYCHOTHERAPY
National phase entry:
Publication Number
WO/2023/131841
Publication Date
13.07.2023
International Application No.
PCT/IB2022/062219
International Filing Date
14.12.2022
Title **
[English]
R-MDMA AND S-MDMA TO ASSIST PSYCHOTHERAPY
[French]
R-MDMA ET S-MDMA POUR AIDER LA PSYCHOTHÉRAPIE
Applicants **
UNIVERSITATSSPITAL BASEL
Inventors
LIECHTI, Matthias Emanuel
Priority Data
63/297,322
07.01.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2171 | |
| EPO | Filing, Examination, Granting | 10656 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2380 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
22,854
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A composition including R-MDMA, S-MDMA, or specific (not 1:1 as in racemic MDMA) combinations of these two enantiomers of racemic MDMA as well as R-MDA, S-MDA, and a combination that is not 1:1 of R-MDA and S-MDA. A method of treating an individual, especially in substance-assisted psychotherapy by administering the composition to the individual. A method of personalized medicine, by evaluating an individual who is in need of MDMA treatment and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment, and administering the composition to the individual. A method of reducing abuse of MDMA by an individual, by administering R-MDMA to the individual and thereby reducing abuse.[French]
La présente invention concerne une composition comprenant de la R-MDMA, de la S-MDMA ou des combinaisons spécifiques (pas dans une proportion de 1:1 comme dans la MDMA racémique) de ces deux énantiomères de la MDMA racémique, ainsi que de la R-MDA, de la S-MDA et une combinaison qui n'est pas dans une proportion de 1:1 de R-MDA et de S-MDA. L'invention concerne également une méthode de traitement d'un individu, en particulier dans le cadre d'une psychothérapie assistée par substance, par l'administration de la composition à l'individu. L'invention concerne une méthode médicale personnalisée, consistant à évaluer un individu qui a besoin d'un traitement à base de MDMA et à déterminer si certaines caractéristiques de l'individu ne conviennent pas à un traitement à base de MDMA, et à administrer la composition à l'individu. L'invention concerne enfin une méthode de réduction de l'abus de MDMA par un individu, consistant à administrer de la R-MDMA à l'individu et à réduire ainsi l'abus.